The drug is approved for the treatment of psoriasis in adult patients who are candidates for systemic therapy and who suffer from chronic moderate-to-severe plaque psoriasis. This most recent approval adds to Enbrel’s previously approved indications of Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis . Amgen reported that the FDA approval was based on data from more than 1200 adults with plaque psoriasis in two Phase III …

Read the rest of this entry